ANEW Medical, Inc. financial data

Symbol
WENA, WENAW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1115 Broadway, 12 Th Floor, New York, NY
Fiscal year end
December 31
Former names
Redwoods Acquisition Corp. (to 6/21/2024)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 18 % +652%
Debt-to-equity -147 % +67.4%
Return On Equity 2.24 %
Return On Assets -0.41 % -118%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.2M shares +95.8%
Common Stock, Shares, Outstanding 15.7M shares +360%
Entity Public Float 56.6M USD -50.2%
Common Stock, Value, Issued 1.57K USD +361%
Weighted Average Number of Shares Outstanding, Basic 15.7M shares +3.63%
Weighted Average Number of Shares Outstanding, Diluted 2.5M shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 0 USD
General and Administrative Expense 1.24M USD +93%
Operating Income (Loss) -1.47M USD -48.5%
Nonoperating Income (Expense) -56K USD -178%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -452K USD -70.8%
Income Tax Expense (Benefit) 484K USD -80.8%
Net Income (Loss) Attributable to Parent -85K USD -104%
Earnings Per Share, Basic -0.03 USD/shares -50%
Earnings Per Share, Diluted -0.03 USD/shares -50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.05K USD
Assets, Current 1M USD +286%
Other Assets, Noncurrent 2.31M USD
Assets 3.31M USD -94.2%
Accounts Payable, Current 34K USD
Accrued Liabilities, Current 250K USD -8.45%
Liabilities, Current 899K USD -33.5%
Deferred Income Tax Liabilities, Net 18.1K USD
Liabilities 4.86M USD -27.7%
Retained Earnings (Accumulated Deficit) -5.54M USD +8.43%
Stockholders' Equity Attributable to Parent -1.55M USD +74.3%
Liabilities and Equity 3.31M USD -94.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -377K USD -0.95%
Net Cash Provided by (Used in) Financing Activities 282K USD -44.7%
Net Cash Provided by (Used in) Investing Activities -70K USD +80.6%
Common Stock, Shares Authorized 1B shares +1900%
Common Stock, Shares, Issued 15.7M shares +360%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -223K USD -13079%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 845K USD +1990%
Deferred Tax Assets, Valuation Allowance 308K USD +175%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 290K USD +775%
Deferred Income Tax Expense (Benefit) 94.8K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares
Additional Paid in Capital 24.7K USD
Preferred Stock, Shares Outstanding 0 shares